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Abstract High plasma homocysteine (Hcy) levels are as-
sociated with increased osteoporotic fracture incidence.
However, the mechanism remains unclear. We investigated
the effect of Hcy-lowering vitamin B12 and folic acid treat-
ment on bone mineral density (BMD) and calcaneal quan-
titative ultrasound (QUS) parameters. This randomized,
double-blind, placebo-controlled trial included participants
aged C65 years with plasma Hcy levels between 12 and
50 lmol/L. The intervention comprised 2-year supplemen-
tation with either a combination of 500 lg B12, 400 lg folic
acid, and 600 IU vitamin D or placebo with 600 IU vitamin
D only. In total, 1111 participants underwent repeated dual-
energy X-ray assessment and 1165 participants under-
went QUS. Femoral neck (FN) BMD, lumbar spine (LS)
BMD, calcaneal broadband ultrasound attenuation (BUA),
and calcaneal speed of sound (SOS) were assessed. After
2 years, FN-BMD and BUA had significantly decreased,
while LS-BMD significantly increased (all p\ 0.01) and
SOS did not change in either treatment arm. No statistically
significant differences between the intervention and placebo
group were present for FN-BMD (p = 0.24), LS-BMD
(p = 0.16), SOS (p = 0.67), and BUA (p = 0.96). How-
ever, exploratory subgroup analyses revealed a small posi-
tive effect of the intervention on BUA at follow-up among
compliant persons [80 years (estimated marginal mean
64.4 dB/MHz for the intervention group and 61.0 dB/MHz
for the placebo group, p = 0.04 for difference). In conclu-
sion, this study showed no overall effect of treatment with
vitamin B12 and folic acid on BMD or QUS parameters in
elderly, mildly hyperhomocysteinemic persons, but suggests
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a small beneficial effect on BUA in persons[80 years who
were compliant in taking the supplement.
Keywords DXA  QUS  Vitamin B12  Folic acid 
Homocysteine
Introduction
Approximately a decade ago, plasma levels of homocys-
teine (Hcy) were discovered to be positively associated
with incident osteoporotic fractures [1, 2]. Vitamin B12
and/or folate are important co-factors in the remethylation
of Hcy to methionine, and high plasma Hcy levels are often
caused by vitamin B12 and/or folate deficiency [3]. Sub-
sequent supplementation with these vitamins has been
shown to be effective in reducing levels of Hcy [4]. Sup-
plementation was, therefore, hypothesized to be associated
with a lower fracture incidence as well. However, inter-
vention studies with B-vitamin supplementation observed
inconsistent effects on fracture prevention [5–8].
The potential mechanism underlying the association
between Hcy and fractures remains to be determined. One
of the hypotheses concerns the role of bone mineral density
(BMD) in this association. Previously, cross-sectional
studies on the relation between Hcy and BMD showed
conflicting results (e.g., [9–11]). Moreover, two trials in-
vestigated the effect of B-vitamin supplementation on
BMD, and both observed no effects [6, 12]. However, these
trials were limited either in size (n = 47) [12] or in gen-
eralizability (hemiplegic post-stroke patients) [6] and both
used fairly high doses of B-vitamins.
Alternatively, Hcy is thought to interfere with collagen
cross-linking in bone, thereby reducing bone quality. This
suggestion is supported by clinical observations in patients
with homocystinuria, among whom bone collagen profiles
are disturbed [13]. Previous cross-sectional data indeed ob-
served inverse associations betweenHcy and bone quality, as
reflected by quantitative ultrasound (QUS) parameters [14–
16]. However, intervention studies on the effect of B-vitamin
supplementation on those QUS parameters are lacking.
The current study investigated the effects of vitamin B12
and folic acid supplementation on BMD and QUS pa-
rameters, that is broadband ultrasound attenuation (BUA)
and speed of sound (SOS), in a large, mildly hyperhomo-
cysteinemic, but otherwise general elderly population.
Materials and Methods
Study Design
The B-PROOF study is a double-blind, randomized,
placebo-controlled multicenter trial. It was primarily
designed to investigate the effect of 2-year oral supple-
mentation with 400 lg folic acid and 500 lg vitamin B12
on osteoporotic fracture incidence in hyperhomocysteine-
mic persons aged 65 years and over [17]. Participants in
both treatment arms additionally received 600 IU of vi-
tamin D daily. Participants (n = 2919) were randomly
assigned to the treatment groups in a 1:1 ratio while
stratifying for study center, sex, age (65–80, C80 years),
and Hcy level (12–18, C18 lmol/L). The random alloca-
tion sequence and randomization were generated and per-
formed using SAS 9.2 by an independent research
dietician. Intervention and placebo tablets were indistin-
guishable in taste, smell, and appearance. Both the par-
ticipants and all researchers and research assistants were
blinded to the study treatment. Treatment effects on BMD
and QUS were predefined secondary outcomes of the
B-PROOF study [17]. Recruitment of participants took
place between September 2008 and March 2011. Details of
the B-PROOF study were described previously [17]. The
B-PROOF study has been registered with the Netherlands
Trial Register http://www.trialregister.nl under identifier
NTR 1333 since June 1, 2008 and with ClinicalTrials.gov
under identifier NCT00696514 since June 9, 2008. The
Medical Ethics Committee of Wageningen University
(WU) approved the study and local feasibility was given by
the Medical Ethics Committees of VU University Medical
Center (VUmc) and Erasmus MC. The study was per-
formed in accordance with the Declaration of Helsinki and
all individual participants gave written informed consent.
Study Population
Inclusion criteria were an age of 65 years or over at
baseline and a plasma Hcy level between 12.0 and
50.0 lmol/L. Exclusion criteria were a serum creatinine
level [150 lmol/L, the presence of cancer in the past
5 years (excluding non-melanoma skin cancer), use of high
doses of B-vitamins (intramuscular injections of vitamin
B12 and/or folic acid intake[300 lg/day) or permanent use
of a wheel chair. For BMD measurements, participants had
to be able to visit one of the study centers. Figure 1 shows
the flow-chart of the study sample.
Basic Characteristics
At baseline, height was measured without shoes to the
nearest millimeter using a stadiometer. Weight was mea-
sured while the participant wore light clothes and no shoes.
Body mass index was calculated as weight/height2. Struc-
tured questionnaires were used to assess fracture history,
current use of medication and supplements, level of educa-
tion, use of alcohol, and current smoking behavior [17].
Anti-osteoporotic medication use was defined as the use of
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bisphosphonates, strontium ranelate, selective estrogen-re-
ceptor modulators, estrogens, androgens, denosumab, or
teriparatide. Blood was withdrawn when the participant was
in a fasted state or had consumed a light, restricted breakfast.
EDTA-blood was placed on ice immediately after being
withdrawn. Plasma Hcy, serum creatinine, folate, vitamin
B12, holotranscobalamin, 25OH-vitamin D and methyl-
malonic acid, and methylenetetrahydrofolate reductase
(MTHFR)-genotype were determined; details of the meth-
ods used have been described previously [8, 17].
Dual-Energy X-ray (DXA) Assessment
In a subsample of 1227 participants, DXA was performed
at baseline. Of these participants, 1111 persons also un-
derwent a DXA after the 2 years of intervention (Fig. 1).
DXA was performed in two of the three study centers. In
VUmc, a Hologic QDR 4500 Delphi device (Hologic Inc.,
USA, CV = 0.45 %) was used. In Erasmus MC, a GE
Lunar Prodigy device (GE Healthcare, USA,
CV = 0.08 %) was used. A scan of the femur was made to
determine the BMD at the femoral neck (FN). The left hip
was scanned, but in case of a prosthesis, the right hip was
scanned. A scan of the lumbar spine (LS) was made to
assess BMD in the vertebrae L1 to L4. Measurements were
performed according to the manufacturer’s protocols.
In Erasmus MC, during the intervention period, a new
scanner of the same type was installed. Follow-up mea-
surements for participants who were measured using the
new device at follow-up were adjusted for results of a
cross-calibration with the old system. A participant’s
baseline and follow-up measurement always took place in
the same study center.
QUS Parameters
QUS parameters of the calcaneus were measured using the
portable Hologic Sahara bone densitometer (Hologic,
USA) (Erasmus MC, VUmc, WU) or the portable CUBA
Clinical system (McCue Ultrasonics, UK) (VUmc). At
baseline, QUS-measurements were performed in 1405
participants. Repeated QUS was available in 1165 par-
ticipants (Fig. 1). Measurements of both the left and right
calcaneus were performed in duplo. Mean broadband ul-
trasound attenuation (BUA, CV = 3.7 %) and speed of
sound (SOS, CV = 0.22 %) were calculated as the average
of these four measurements. Measurements were excluded
if the expected linear frequency-attenuation relation was
violated, because this indicates invalid results.
Compliance
Participants were asked to return the remaining study
tablets every 6 months during their 2-year intervention
period. Participants were regarded as compliant to the
study treatment when at least 80 % of the tablets had been
taken during the intervention period, as indicated by the
number of returned tablets. Compliance of participants who
dropped out of the study was calculated over the planned
full study period of 2 years.
Fig. 1 Flow-chart regarding DXA and QUS-measurements in the B-PROOF study
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Adverse Events
Adverse events were reported by the participants on their
study calendar or via telephone, as has been described
previously [8].
Sample Size Calculation and Statistical Analyses
Based on an expected increase in BMD of 0.027 g/cm2
(extrapolated from [18], who observed a 1-year-change in
spinal BMD of 0.0135 when folate levels increased with
15 nmol/L) between the two treatment groups, an SD of
0.18 g/cm2 and a power of 80 % to detect this difference,
we estimated that 541 participants had to be included in
both treatment arms. Similarly, a decline in BUA of
2.1 dB/MHz is expected in 2 years in the placebo group,
and we expect this decline to be prevented in the inter-
vention group (extrapolated from [19]). With a difference
of 2.1 dB/MHz and an SD of 9.4, 316 participants per
group would be needed.
All statistical analyses were performed according to a
predefined analysis plan. Differences in baseline charac-
teristics between the two treatment groups were tested
using a t test for continuous traits and a Chi-squared test for
categorical traits. If a variable was non-normally dis-
tributed, a Mann–Whitney U test was used. Two-year
changes in markers of B-vitamins (Hcy, folate, vitamin
B12, methylmalonic acid, and holotranscobalamin) within
treatment groups were tested using Wilcoxon signed-rank
tests. Changes between treatment groups were tested with
independent samples t tests.
In the primary intention-to-treat analyses, all par-
ticipants of whom both baseline and follow-up data were
available were included. In the secondary per-protocol
analyses, only compliant participants were included.
Paired t tests were done to assess the difference within
treatment groups between baseline and follow-up for all
outcomes. To test the difference in outcomes after 2 years
of treatment between the intervention group and the
placebo group, analysis of covariance (ANCOVA) was
performed. In addition to the baseline value of the out-
come of interest (FN-BMD, LS-BMD, BUA, or SOS), sex
and age were entered as covariate in the basic model.
This was defined as the primary analysis. Next, other
potential confounders, defined by a p-value of the dif-
ference between the treatment arms\0.2, were entered in
the model. They were retained in the fully adjusted model
if they changed F of the treatment in the basic model with
at least 10 %. This was done for each outcome separately.
For BMD, analyses were repeated after stratification for
study center, since both centers used different DXA-de-
vices, which are known to produce systematically differ-
ent results.
Interactions between treatment and baseline age, sex,
and Hcy were investigated in exploratory analyses. Strati-
fied analyses were performed if the interaction term was
statistically significant. All statistical analyses were per-
formed using IBM SPSS Statistics 20. Level of significance
was set at a = 0.05.
Results
Table 1 shows the general characteristics at baseline of
1111 participants with repeated DXA and of 1165 par-
ticipants with repeated QUS. At baseline, LS-BMD was
higher in the intervention group compared with the placebo
group (1.14 vs 1.11 g/cm2, respectively, p = 0.03). In the
BMD-sample, levels of serum holotranscobalamin were
slightly higher in the intervention group (70 vs 65 lmol/L,
p = 0.03). In the QUS-sample, participants in the placebo
group more often had a positive fracture history (45 vs
35 %, p\ 0.01).
A total of 611 participants had both FN-BMD as well as
QUS available at baseline and at follow-up. At baseline,
FN-BMD correlated significantly with both BUA
(r = 0.48, p\ 0.01) and SOS (r = 0.42, p\ 0.01).
Changes in levels of Hcy, folate, vitamin B12, methyl-
malonic acid, and holotranscobalamin are shown in
Table 2. Hcy changed significantly in the intervention
group only. The other markers changed in both the inter-
vention (improvements only) and placebo group (both
improvements and deteriorations). p for differences in
change between the groups was \0.001 for all markers,
indicating that the compliance was good. Similar findings
were observed in the QUS-sample.
BMD Effects
Baseline and follow-up BMD per treatment group are
shown in Table 3. FN-BMD significantly decreased in both
treatment groups. On the contrary, LS-BMD increased
significantly in both treatment groups. BMD in both the FN
(0.84 g/cm2 (95 % CI 0.834–0.839) in the intervention
group vs 0.83 g/cm2 (95 % CI 0.831–0.837) in placebo
p = 0.24), and LS (1.14 g/cm2 (95 % CI 1.134–1.142) vs
1.13 g/cm2 (95 % CI 1.130–1.138), respectively, p = 0.16)
were not significantly different between treatment groups
(Fig. 2). This did not change after adjusting for other po-
tential confounders (holotranscobalamin and vitamin B12).
No statistically significant interaction was observed. When
the analyses were stratified for study center, as pre-speci-
fied, similar results were obtained. For FN-BMD, in
VUmc, estimated means after 2 years were 0.717 (95 % CI
0.712–0.722) and 0.719 (95 % CI 0.714–0.724) g/cm2 in
the placebo and intervention groups, respectively. In
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Table 1 Baseline characteristics for B-PROOF participants with DXA at baseline and follow-up (N = 1111) and for participants with QUS at
baseline and follow-up (n = 1165)
BMD QUS
Placebo Intervention Placebo Intervention
N = 563 N = 548 N = 587 N = 578
Age (years)a 72.8 (5.4) 72.4 (5.6) 73.3 (73.3) 73.4 (73.4)
Sex (% female) 48.3 48.2 57.4 53.8
Hcy (lmol/L)b 14.3 [12.9–16.3] 14.3 [12.9–16.0] 14.3 [12.9–16.4] 14.2 [13.0–16.1]
Creatinine (lmol/L)b 80 [71–93] 82 [71–93] 79 [70–92] 82 [70–93]
Folate (nmol/L)b 19.1 [14.8–25.4] 19.8 [15.4–24.8] 19.1 [14.8–24.5] 18.9 [15.6–24.6]
B12 (pmol/L)
b 269 [204–343] 286 [218–348] 268 [204–352] 270 [216–346.3]
Methylmalonic acid (lmol/L)b 0.21 [0.17–0.29] 0.21 [0.17–0.28] 0.22 [0.18–0.30] 0.23 [0.18–0.30]
Holotranscobalamin (pmol/L)b 65 [47–88]* 70 [50–91]* 65 [45–85] 66 [49–88]
Vitamin D (25OH) (nmol/L)b 52.6 [37.1–70.3] 53.3 [37.2–73.0] 55.7 [39.2–72.4] 56.0 [37.4–75.1]
MTHFR-genotype (%)
CC 43.1 47.9 43.2 47.4
CT 41.9 40.1 46.3 39.2
TT 15.0 12.0 10.5 13.4
Height (cm)a 169.9 (8.9) 170.4 (9.0) 168.5 (8.8) 168.9 (9.2)
Weight (kg)a 77.7 (12.9) 78.5 (13.0) 76.7 (12.2) 76.6 (12.5)
BMI (kg/m2)a 26.9 (3.9) 27 (3.8) 27.0 (3.9) 26.8 (3.8)
Smoking status (%)
Current 8.7 8.4 7.5 10.0
Former 58.6 56.9 55.2 56.2
Never 32.7 34.7 37.3 33.7
Alcohol consumption (%)
No/light 62.9 64.4 64.9 67.3
Moderate 31.8 31.2 30.7 28.4
Excessive 4.8 3.6 3.9 3.5
Very excessive 0.5 0.7 0.5 0.9
Level of education (%)
Low 54.8 52.2 53.6 52.6
Middle 19.9 18.8 22.2 20.4
High 25.3 29.0 24.2 27.0
Study center (%)
VUmc 35.7 32.5 35.4 36.2
Wageningen UR – – 20.4 21.1
Erasmus MC 64.3 67.5 44.1 42.7
Users of folic acid and/or vit. B12 (%) 17.1 14.6 17.4 14.4
Osteoporotic medication use (%) 6.4 7.5 8.9 10.4
Positive fracture history (%) 41.4 39.1 45.0* 35.3*
FN-BMD (g/cm2)a 0.84 (0.15) 0.85 (0.17) – –
T-score FN-BMDa -1.23 (0.93) -1.15 (1.04) – –
LS-BMD (g/cm2)a 1.11 (0.22)* 1.14 (0.25)* – –
T-score LS-BMDa -0.3 (1.7) -0.1 (1.9) – –
BUA (dB/MHz)a – – 70.9 (16.8) 71.8 (17.6)
SOS (m/s)a – – 1537 (31) 1539 (33)
BMD bone mineral density, QUS quantitative ultrasound, BMI body mass index, FN femoral neck, LS lumbar spine, MTHFR methylenete-
trahydrofolate reductase
* p-value\ 0.05
a Presented as mean (standard deviation)
b Presented as median [interquartile range]
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Erasmus MC, these values were 0.896 (95 % CI
0.892–0.899) and 0.898 (95 % CI 0.895–0.902) g/cm2,
respectively. For LS-BMD, in VUmc, estimated means
after 2 years were 1.018 (95 % CI 1.011–1.024) and 1.017
(95 % CI 1.010–1.024) g/cm2 in the placebo and inter-
vention groups, respectively. In Erasmus MC, corre-
sponding values were 1.202 (95 % CI 1.197–1.207) and
1.208 (95 % CI 1.203–1.212) g/cm2. All differences were
non-significant.
In the per-protocol analyses, 1069 participants were
included, and results were similar to the intention-to-treat
analyses (data not shown).
QUS Effects
A significant 2-year decline in BUA was observed in both
the intervention group and the placebo group (both
p\ 0.01), whereas SOS levels did not change significantly
in any of the groups (Table 3). Changes in BUA and SOS
were not significantly different between treatment groups
after adjustments for age, sex, and baseline values of BUA/
SOS (Fig. 3a, b). The estimated marginal means for BUA
were 69.0 dB/MHz (95 % CI 68.4–69.6) in both the in-
tervention group and in the placebo group (p = 0.96), and
the estimated marginal means for SOS were 1538.1 m/s
(95 % CI 1536.6–1539.6) in the intervention group versus
1537.6 m/s (95 % CI 1536.2–1539.1) in the placebo group
(p = 0.67). Additional adjustments for fracture history,
holotranscobalamin, smoking, vitamin B supplement use
and MTHFR-genotype (BUA), or fracture history, smok-
ing, and MTHFR-genotype (SOS) did not change the
findings (data not shown). No interactions with age, sex,
and baseline Hcy concentration were observed.
Results of the per-protocol analyses, including 1097
participants, did not substantially differ from the intention-
to-treat analyses (data not shown). Yet, in the analyses with
BUA as outcome, the interaction with age was significant
(p = 0.02). Exploratory, stratified analyses showed no
effect among persons B80 years, but among persons
[80 years, a significant beneficial effect of the treatment
was observed (p = 0.04, Fig. 4). The estimated marginal
means were 64.4 dB/MHz (95 % CI 62.1–66.6) in the in-
tervention group versus 61.0 dB/MHz (95 % CI 58.8–63.3)
in the placebo group.
Discussion
This randomized controlled trial did not show an overall
effect of 2-year oral folic acid and vitamin B12 supple-
mentation on BMD and QUS parameters compared with
the placebo. In a subgroup of persons[80 years who were
compliant with the study protocol, a small but statisticallyT
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significant positive effect of the B-vitamin intervention was
observed on BUA.
This study is the first trial investigating the effects of
vitamin B12 and folic acid on QUS. Moreover, effects on
BMD have not been studied before in a large, mildly hy-
perhomocysteinemic, but otherwise general older popula-
tion. Two previous trials have been conducted, showing
results that are in concordance with our findings. A Ja-
panese trial investigated the effect of 1.5 mg vitamin B12
and 5 mg folic acid on hip fracture incidence and meta-
carpal BMD in hemiplegic post-stroke patients. In that
study, no effect of a 2-year treatment on BMD was ob-
served, while fracture incidence was strongly and sig-
nificantly reduced in this specific population [6]. In
addition, a small trial (n = 47) has been performed which
investigated the effect of a 1-year treatment with vitamin
B12, B6, and folic acid on BMD among osteoporotic pa-
tients [12]. Overall, no effects were observed in that study.
However, in participants with Hcy[15 lmol/L (n = 8 in
the intervention group), a significant increase in T-score
was seen. In our study, no interaction effect of the treat-
ment with baseline Hcy levels was observed. It should be
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Fig. 2 Estimated mean FN-BMD (a) and LS-BMD (b) after 2 years
of intervention, adjusted for baseline FN-BMD/LS-BMD, age, and
sex
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Fig. 3 Estimated mean BUA (a) and SOS (b) after 2 years of
intervention, adjusted for baseline BUA/SOS, age, and sex
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Fig. 4 Estimated mean BUA among compliant persons [80 years
after 2 years of intervention, adjusted for baseline BUA, age, and sex
Table 3 Bone mineral density (n = 1111) and quantitative ultrasound parameters (n = 1165) at baseline and follow-up
Placebo Intervention
Baseline Follow-up p-value Baseline Follow-up p-value
FN-BMD (g/cm2) 0.84 (0.15) 0.83 (0.15) \0.01 0.85 (0.17) 0.85 (0.17) \0.01
LS-BMD (g/cm2) 1.11 (0.22) 1.12 (0.22) \0.01 1.14 (0.29) 1.15 (0.25) \0.01
BUA (dB/MHz) 70.9 (16.8) 68.5 (17.4) \0.01 71.8 (17.6) 69.4 (17.9) \0.01
SOS (m/s) 1537 (31) 1537 (33) 0.25 1540 (34) 1539 (35) 0.46
FN femoral neck, LS lumbar spine, BMD bone mineral density, BUA broadband ultrasound attenuation, SOS speed of sound. Presented as mean
(standard deviation)
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noted that in comparison to our study, Herrmann et al. used
higher doses (2.5 mg folic acid, 25 mg B6, and 500 lg B12)
[12].
QUS parameters are largely determined by BMD, but
bone microarchitecture is an important determinant as well,
independent of BMD [20]. QUS has been shown to be an
independent predictor for fracture risk [21]; a decrease of 1
SD in BUA has been associated with a 1.4 fold increased
risk of any clinical fracture [21]. We observed a mean
difference in BUA of 3.4 dB/MHz (5.2 % of mean baseline
BUA) between the intervention and placebo group among
compliant persons [80 years. The observed difference
between the groups was larger than the coefficient of var-
iation (5.2 vs 3.4 %). However, because the spreading of
BUA is relatively large (SD = 17.1), the observed effect
will be of minor importance on population level. However,
when applying a longer duration of intervention, it might
become clinically relevant.
We observed an effect on BUA in the subgroup of
compliant persons[80 years, but no effect on SOS was
observed. Although the correlation between BUA and SOS
is strong (R = 0.7), their measurement is based on differ-
ent constructs. In addition, they have been shown to be
influenced by a different set of independent determinants
[22]. These differences may explain the different effects on
BUA and SOS. However, a chance finding cannot be ruled
out either.
Recently, we have shown within the B-PROOF study
that fracture incidence was lower in the intervention group
compared with placebo only when specifically addressing
compliant participants aged 80 years or over [8]. The
currently reported change in BUA might partly explain this
age-specific treatment effect, and supports the suggestion
of the role of homocysteine in bone collagen cross-linking.
Unfortunately, we were not able to test the hypothesis of
BUA as mediator in the age-specific treatment effect on
fractures, due to a too low absolute number of fractures
among participants [80 years of whom BUA data were
available (n = 23). Alternatively, the lack of an effect on
BMD does not completely rule out the possibility of BMD
as a mediator. Participants of the DXA-subsample had to
be able to visit one of the study centers and may therefore
not be fully representative of the complete study popula-
tion: as compared to the total sample, the DXA-subsample
was significantly younger (mean age 72.6 vs 74.1,
p\ 0.01), with a lower percentage of persons aged
[80 years (9.0 vs 16.9 %, p\ 0.01). In line with this, the
subgroup of persons aged[80 years with DXA was also
significantly younger than the subgroup of the complete
study population (mean age 83.9 vs 85.1, p\ 0.01). The
somewhat selective sample hampers definite conclusions
about the absence of an effect of B-vitamins on BMD in
persons[80 years.
It should be noted that LS-BMD increased in both
treatment groups during 2 years of intervention, while FN-
BMD decreased. In older persons, an increase in LS-BMD
can be expected due to, for instance, degenerative changes
of the spine [23, 24]. Our observation therefore supports
the presumption that LS-BMD may not be a valid indicator
of osteoporosis at high age [25]. It could be regarded as a
limitation that baseline levels of BMD in this randomized
controlled trial differed significantly between the inter-
vention and placebo group. However, we adjusted for
baseline BMD, and therefore we assume that this did not
influence the results of the analyses. Another limitation of
the study is the fact that all participants received 600 IU
vitamin D daily, which is in line with the guidelines of the
Dutch Health Council [26]. In the past, vitamin D sup-
plementation with 400 IU daily has been shown to influ-
ence BMD up to 2.6 % [27, 28]. Effects of vitamin D may
therefore have masked the possibly small effects of vitamin
B12 and folic acid on BMD.
From the current study, we conclude that there is no
overall effect of 2-year treatment with vitamin B12 and
folic acid on BMD or QUS in hyperhomocysteinemic
elderly people. Among elderly[80 years who were com-
pliant in taking the supplement, a positive effect of the
treatment on BUA was observed. This might partly explain
the previously reported reduction in fracture risk in the
same subgroup [8]. It is important to note that an adverse
effect of our treatment with vitamin B12 and folic acid on
cancer incidence was observed, as has been published
previously [8], implying caution in designing further re-
search. Nonetheless, research on effects of B-vitamin
treatment on other mechanisms, for instance on bone
markers, computed tomography, or potentially the
relatively new assessment of trabecular bone score, is
warranted to reveal the additional pathways by which vi-
tamin B12 and folic acid exert a potential anti-fracture ef-
fect in hyperhomocysteinemic elderly.
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